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Myocardial infarction (MI), the top cause of 
death globally, is associated with a high risk of 
heart failure development. The prognosis of MI 
depends on the ischemia size, which is correlated 
with the time from the onset of symptoms to reper-
fusion. Percutaneous coronary intervention (PCI) 
is a well-established treatment option for patients 
with MI [1]. In recent years, the most significant 
emphasis has been placed on the development of 
cardiology hubs of local networks that provide the 
shortest time to revascularization and improve-
ment of MI treatment outcomes [2]. Moreover, 
managed care after MI has significantly improved 
results by increasing rates of cardiac recovery, 
complete revascularization, or implantation of an 
implantable cardioverter-defibrillator [3]. This 
situation has changed dramatically since the be-
ginning of the pandemic of coronavirus disease 
(COVID-19), where over a very short period of 
time, an increased number of infected people were 
seeking medical assistance. COVID-19 confers the 
risk of severe acute respiratory syndrome caused 
by severe respiratory tract infection. Since the 
beginning of the pandemic, health systems have 
struggled to reorganize their health priorities due 
to the overwhelming number of patients requir-
ing assistance and limited medical equipment. 
Emergency departments were transformed to be 
specifically dedicated to COVID-19 management. 
Many governmental authorities recommended the 
use of social distancing and ‘stay at home and away 
from others,’ as a means to control the spread of 
these infections and to be able to provide medical 
equipment and staff to treat those patients already 
hospitalized. While MI networks were and can 
presently  still provide care for patients with MI, 
this care now involves another layer of caution. 
COVID-19 has changed the nature of medical con-
sultations after MI, emphasizing virtual consulting 
with patients. The first patients of COVID-19 were 
reported in December of 2019 in Wuhan, China, 
and rapidly spread to the rest of the world [4, 5]. 
In Europe, northern Italy was the first affected 
region with the highest total case count and an 
exponential increase in the number of cases. What 
was observed in the MI care networks, was that 
many patients with the acute coronary syndrome 
(ACS) refrained from obtaining emergency medical 
services for fear of acquiring COVID-19 infection 
in the hospitals overwhelmed with COVID-19 
patients. This dramatic situation was reported 
all over the world as catheterization laboratories 
noted a dramatic reduction of ACS patients and 
an increase in mortality, which could not be solely 
explained by complications caused by COVID-19. 
Specifically, data from northern Italy showed 
a drastic reduction in the number of ACS patients 
reporting to cardiovascular centers at the time of 
the COVID-19 outbreak [6]. A comparable situa-
tion was observed in the United States of America, 
where during the early phase of the COVID-19 
pandemic, the reduction of PCI in ST-segment 
elevation myocardial infarction (STEMI) patients 
was 38% [7]. The data from Spain was also alarm-
ing, which showed a 40% decrease in the number 
of PCI in STEMI patients [8], while in Switzerland, 
STEMI referrals decreased by 56% [9]. Data from 
Poland [10, 11] showed a greater decline in the 
number of procedures for non-STEMI (NSTEMI), 
unstable angina or chronic coronary syndrome than 
in those for STEMI. Legutko et al. [10] reported 
that after lockdown the number of PCI in STEMI 
decreased by 19.2%, while in a later period it de-
clined by 16.2%. Conversely, the decrease of PCI 
procedures in NSTEMI after lockdown was more 
pronounced and reached 33.5%, while later on it 
even reached 36.1%. However, Siudak et al. [11] 
noted that in comparison to the corresponding 
period of the previous year there was a reduction 
in PCI of 36% for STEMI and 39% for NSTEMI. 
The statistics from other countries would presum-
ably demonstrate similar trends; however, more 
data in this field has not yet been published. The 
data revealed that patients with ACS requiring PCI 
had been undertreated. A natural consequence of 
this situation is the growth in MI complications, 
translating into increased morbidity and mortal-
ity. Thus, this aspect of care for cardiac patients 
requires urgent attention. In addition to all the 
information relayed to the general public about 
the COVID-19 pandemic, the need for immediate 
contact with emergency medical services in case of 
chest pain should be emphasized. Hospitals should 
continue to use COVID-19 protocol, but healthcare 
professionals should continuously be aware of the 
fact that ACSs still represent the leading cause of 
death in a broad population despite current epide-
miologic status. Although ACS may be accompa-
nied by active COVID-19 infection, or even worse 
[12], COVID-19-associated myocarditis may mimic 
ACS [13], the need for urgent invasive coronary 
angiography in ST-segment elevation ACS is still 
of vital importance and should not be neglected 
[12]. This does not prevent the need for caution of 
infection, and presumably, each patient with ACS 
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should be regarded as COVID-19 positive until 
a negative test result is obtained. Nasopharyngeal 
swab for COVID-19 infection should be acquired 
in all patients upon admission, while all medical 
staff should be provided with adequate personal 
protection equipment against COVID-19. This was 
recently stressed in a consensus document by the 
European Association of Percutaneous Coronary 
Interventions (EAPCI) [14]. Only in this way can 
we improve the treatment outcomes of patients 
with ACS during a pandemic period. Let us not 
waste the decades of progress in the field of inva-
sive MI treatment!
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